Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...

Novo Nordisk Pipelines Oral Obesity Drugs As Shares Face Steep Pressure

Novo Nordisk (CPSE:NOVO B) has entered a new $2.1b partnership with Vivtex to develop next generation oral biologic drugs for obesity and diabetes. The collaboration targets oral versions of medicines ...

Novo Nordisk and Vivtex collaborate for oral medicines development

Vivtex is set to receive research funding, upfront payments, milestone payments up to $2.1bn, and tiered royalties.
The Manila Times

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global ...
Nasdaq

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese ...

REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today ...
Seeking Alpha

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

Extensive nonclinical studies of THB001 identified a potential mechanistic basis for observed hepatotoxicity; structural modifications introduced in THB335 believed to address this risk U.S.
Nasdaq

Vaxart Initiates Phase 1 Trial For Second-Generation Oral Norovirus Vaccine

(RTTNews) - Vaxart, Inc. (VXRT) announced on Tuesday that it has initiated a Phase 1, open-label, dose-ranging clinical trial for its second-generation oral norovirus vaccine. The trial is designed to ...
Seeking Alpha

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s second-generation norovirus vaccine candidate, which ...
Morningstar

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien ...

Novo Nordisk A/S: Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Partnership will leverage Vivtex's proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global ...